RT Journal Article
SR Electronic
T1 Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.01.24306727
DO 10.1101/2024.05.01.24306727
A1 Kao, David P
A1 Martin, James
A1 Aquilante, Christina
A1 Shalowitz, Elise L
A1 Leyba, Katarina
A1 Kudron, Elizabeth
A1 Reusch, Jane EB
A1 Regensteiner, Judith G.
YR 2024
UL http://medrxiv.org/content/early/2024/05/03/2024.05.01.24306727.abstract
AB Objective Determine whether statin-associated DM is reported more frequently in women than men in post-marketing adverse drug event (ADE) surveillance.Design Retrospective pharmacovigilance analysisData source Publicly available FDA Adverse Event Reporting System (FAERS) from January 1997 through December 2023.Setting Real-world spontaneously reported ADEs in the United States.Participants Community patients reporting statin ADEs during the study period.Interventions/exposures Adverse drug event reports that included at least one statin.Main outcome measures Proportional reporting ratio to identify increased rates of statin-associated DM events in women and men compared with all other medications, and reporting odds ratio to compare reporting rates in women vs. men.Results A total of 18,294,814 ADEs were reported during the study period. Among statin-associated ADEs, 14,897/519,209 (2.9%) reports mentioned DM in women compared with 7,412/489,453 (1.5%) in men, which were both significantly higher than background (0.6%). Statins were primary-or secondary-suspected cause of the ADE significantly more often in women than men (59.8 vs. 28.7%), and reporting rates were disproportionately higher in women than in men for all statins. (reporting odds ratio 1.9 [95% CI 1.9-2.0]). The largest difference in reporting of statin-associated DM between women and women was observed with atorvastatin.Conclusions Analysis post-marketing spontaneous ADE reports demonstrated a higher reporting rate of DM-associated with statin use compared to other medications with a significantly higher reporting rate in women compared to men. Future studies should consider mechanisms of statin-associated DM moderated by sex.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The raw data used in this study is publicly available at https://open.fda.gov/data/faers/). The drug names and ingredients of FDA approved products is available at https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files. The MedDRA terminology is available with a license at https://www.meddra.org/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw data used in this study is publicly available at https://open.fda.gov/data/faers/). The drug names and ingredients of FDA approved products is available at https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files. The MedDRA terminology is available with a license at https://www.meddra.org/. The R mdsstat analysis package is at https://rdrr.io/cran/mdsstat/. Analysis code and access to our FAERS BigQuery repository containing linked versions of the above resources are available on reasonable request.